Aug. 7 at 11:41 AM
$VIR Stringer also underscores that the HDV opportunity, which he estimates at over
$1B in potential sales and possibly higher with broader diagnosis, is not fully reflected in the current share price. Based on robust Phase 2 results, he views the elebsiran/tobevibart combination as a potential best-in-class option, and notes that recent U.S. approval of a competing HDV therapy and broader HDV testing initiatives are helping to build the market, reinforcing his positive stance and unchanged
$18 price target.
